– USA, MD – Cerecor, Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced the appointment of Keith Schmidt to its Board of Directors effective immediately. Mr. Schmidt joins the Cerecor Board as a member of the Audit Committee, the Compensation Committee, and an independent director serving a term ending at the 2019 Annual Meeting.
“We are delighted to welcome Keith to our Board,” said Dr. Simon Pedder, Executive Chairman of the Board of Cerecor, “with his experience in new product development and commercialization, Keith is a key addition for the Company. We believe he will provide valuable insights and strategic guidance as we continue to progress both our in-line commercial products as well as prepare for commercialization and launch of our innovative pipeline assets.”
About Keith Schmidt
Mr. Keith W. Schmidt, M.B.A. previously was the Chief Commercial Officer of Chelsea Therapeutics International Ltd. prior to its sale to H. Lundbeck A/S in 2014. Mr. Schmidt has over 35 years of experience and an outstanding reputation and proven track record in domestic and international pharmaceutical sales, and strategic marketing for launching industry-leading drugs including Pegasys, Naprosyn, Anaprox, Cialis, Cymbalta, and Strattera. Mr. Schmidt served as President of Tellico Pharma LLC. and served as Vice President of Thomson Healthcare Advanced Therapeutics Communications. Over the course of his career, Mr. Schmidt has worked for such companies as Hoffmann-La Roche AG and Syntex Laboratories, Inc. During his tenure at Hoffmann-La Roche, he served as International Business Leader responsible for global pre-launch marketing preparation, launch market plans, and life cycle planning for Pegasys in Hepatitis C, Hepatitis B, and Oncology. At Roche, he developed and led the global sales and marketing launch efforts for Pegasys and Copegus. Prior to joining Roche, Mr. Schmidt served in a number of progressively senior positions at Syntex Laboratories, variously directing New Product Development, Sales Force Strategies, OBYN Sales, and Sales Training.
“I am pleased for the opportunity to serve as a member of Cerecor’s Board,” said Mr. Schmidt. “I look forward to applying my cross-functional skills and experiences in guiding future commercialization strategies and current in-market products as the Company moves forward.”
Mr. Schmidt earned a Bachelor of Science from South Dakota State University and an MBA from the University of San Francisco.
Cerecor is a fully integrated biopharmaceutical company with commercial operations and research and development capabilities. The Company is building a robust pipeline of innovative therapies in orphan rare diseases, neurology, and pediatric healthcare. The Company’s pediatric orphan rare disease pipeline is led by CERC-801, CERC-802, and CERC-803, which are therapies for inborn errors of metabolism specifically disorders known as Congenital Disorders of Glycosylation. The FDA granted Rare Disease Designation and Orphan Drug Designation to all three CERC-800 compounds, thus qualifying them for receipt of a Priority Review Voucher upon approval of a new drug application. The PRV may be sold or transferred an unlimited number of times. The Company plans to leverage the 505 NDA pathway for all three compounds to accelerate development and approval. The Company is also in the process of developing one other preclinical pediatric orphan rare disease compound for the treatment of mitochondrial DNA Depletion Syndrome. The Company’s neurology pipeline is led by CERC-301, which Cerecor is currently exploring as a novel treatment for neurogenic orthostatic hypotension. The Company is also developing two other neurological compounds; CERC-406 for Parkinson’s Disease, CERC-611 for epilepsy. The Company also has a diverse portfolio of marketed products. Our marketed products are led by our prescribed dietary supplements and prescribed drugs. Our prescribed dietary supplements include Poly-Vi-Flor and Tri-Vi-Flor which are prescription vitamin and fluoride supplements used in infants and children to treat or prevent deficiency of essential vitamins and fluoride. The Company also markets a number of prescription drugs that treat a range of pediatric diseases, disorders, and conditions. Cerecor’s prescription drugs include AcipHex, Cefaclor for Oral Suspension, Karbinal ER, Sprinkle, Millipred and Ulesfia.
For more information: http://www.cerecor.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.